Guardion Health Science (GHSI) Year-over-year earnings per share growth for the last twelve months

Guardion Health Science (GHSI) is facing pressure from marketing expenses and a narrow product portfolio, which is currently being optimized through asset sales. The quarterly percentage growth in earnings per share reflects current development dynamics, where the latest parameter stands at -62.60. Management is focusing on expanding distribution and providing scientific validation for the efficacy of its ophthalmological nutraceuticals.

Guardion Health Science (GHSI) is developing a nutraceutical ecosystem for the therapy of retinal degeneration, where stable revenue is secured by low patient churn and physician recommendations. This process is digitized through a daily recalculation of the quarterly change in net income per share, allowing for the tracking of business growth rates between reports and avoiding entry into the asset at the peak of the quarterly earnings per share growth rate.